Abarelix acetate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 574014

CAS#: 785804-17-3 (acetate)

Description: Abarelix acetate is a synthetic third generation gonadotropin-releasing hormone receptor (GnRHR) antagonist. It increases histamine release from rat peritoneal mast cells in vitro and from a human skin model ex vivo. In vivo, abarelix decreases plasma luteinizing hormone (LH) levels six hours post-treatment in castrated rats, with levels returning to baseline within 24 hours.3 Abarelix (2 mg/kg) also transiently decreases plasma testosterone levels in intact rats, with levels returning to baseline within seven days post-treatment. Formulations containing abarelix have previously been used in the treatment of advanced prostate cancer.

Chemical Structure

Abarelix acetate
CAS# 785804-17-3 (acetate)

Theoretical Analysis

MedKoo Cat#: 574014
Name: Abarelix acetate
CAS#: 785804-17-3 (acetate)
Chemical Formula: C74H99ClN14O16
Exact Mass: 1474.7052
Molecular Weight: 1476.14
Elemental Analysis: C, 60.21; H, 6.76; Cl, 2.40; N, 13.28; O, 17.34

Price and Availability

Size Price Availability Quantity
1.0mg USD 320.0 2 Weeks
5.0mg USD 630.0 2 Weeks
10.0mg USD 1050.0 2 Weeks
25.0mg USD 1900.0 2 Weeks
Bulk inquiry

Related CAS #: 785804-17-3 (acetate)   183552-38-7 (free base)    

Synonym: Abarelix acetate

IUPAC/Chemical Name: N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide, acetate salt


InChi Code: InChI=1S/C72H95ClN14O14.C2H4O2/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47;1-2(3)4/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96);1H3,(H,3,4)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+;/m1./s1

SMILES Code: CC(N[C@H](CC1=CC(C=CC=C2)=C2C=C1)C(N[C@H](CC3=CC=C(Cl)C=C3)C(N[C@H](CC4=CC=CN=C4)C(N[C@@H](CO)C(N(C)[C@@H](CC5=CC=C(O)C=C5)C(N[C@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCNC(C)C)C(N6CCC[C@H]6C(N[C@H](C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C)=O

Appearance: A crystalline solid

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1476.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in- class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol. 2006 Dec;2(6):677-96. doi: 10.2217/14796694.2.6.677. PMID: 17155895.

2: Hogle WP. Abarelix (plenaxis). Clin J Oncol Nurs. 2004 Dec;8(6):663-5. doi: 10.1188/04.CJON.663-669. PMID: 15637961.

3: Abarelix: abarelix-depot-F, abarelix-depot-M, abarelix-L, PPI 149, R 3827. Drugs R D. 2003;4(3):161-6. doi: 10.2165/00126839-200304030-00004. PMID: 12757402.

4: Kirby RS, Fitzpatrick JM, Clarke N. Abarelix and other gonadotrophin- releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x. PMID: 20053189.

5: Mongiat-Artus P, Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother. 2004 Oct;5(10):2171-9. doi: 10.1517/14656566.5.10.2171. PMID: 15461552.

6: Reddy GK. Abarelix (Plenaxis): a gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer. Clin Prostate Cancer. 2004 Mar;2(4):209-11. doi: 10.1016/s1540-0352(11)70046-4. PMID: 15072602.

7: Doehn C, Jocham D. Technology evaluation: Abarelix, Praecis pharmaceuticals. Curr Opin Mol Ther. 2000 Oct;2(5):579-85. PMID: 11249760.

8: Retraction statement: Reconstitution of Plenaxis® (Abarelix) 100 mg for injection is more effective with a vortex-like mixer than when performed manually. J Pharm Pract. 2010 Feb;23(1):78. doi: 10.1177/0897190009360369. PMID: 21507797.

9: Beer TM, Ryan C, Bhat G, Garnick M; Abarelix Study Group. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study. Anticancer Drugs. 2006 Oct;17(9):1075-9. doi: 10.1097/01.cad.0000231476.84782.55. PMID: 17001181.

10: Abarelix (Plenaxis) for advanced prostate cancer. Med Lett Drugs Ther. 2004 Mar 15;46(1178):22-3. PMID: 15037857.

11: Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol. 2001 May;165(5):1585-9. PMID: 11342922.

12: Wong SL, Lau DT, Baughman SA, Menchaca D, Garnick MB. Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. Clin Pharmacol Ther. 2003 Apr;73(4):304-11. doi: 10.1016/s0009-9236(02)17637-5. PMID: 12709720.

13: Koch M, Steidle C, Brosman S, Centeno A, Gaylis F, Campion M, Garnick MB; Abarelix Study Group. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology. 2003 Nov;62(5):877-82. doi: 10.1016/s0090-4295(03)00656-3. PMID: 14624912.

14: Garnick MB, Mottet N. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. BJU Int. 2012 Aug;110(4):499-504. doi: 10.1111/j.1464-410X.2011.10708.x. Epub 2011 Nov 16. PMID: 22093775.

15: Wong SL, Lau DT, Baughman SA, Fotheringham N, Menchaca D, Garnick MB. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. J Clin Pharmacol. 2004 May;44(5):495-502. doi: 10.1177/0091270004264920. PMID: 15102870.

16: McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Garnick MB; Abarelix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology. 2001 Nov;58(5):756-61. doi: 10.1016/s0090-4295(01)01342-5. PMID: 11711355.

17: Beer TM, Garzotto M, Eilers KM, Lemmon D. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin- releasing hormone agonist therapy. J Urol. 2003 May;169(5):1738-41. doi: 10.1097/01.ju.0000059584.47272.9d. PMID: 12686821.

18: Beer TM, Garzotto M, Eilers KM, Lemmon D, Wersinger EM. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy. Urology. 2004 Feb;63(2):342-7. doi: 10.1016/j.urology.2003.09.045. PMID: 14972486.

19: Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol. 2000 Fall;4(3):275-7. PMID: 11062384.

20: Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M, Garnick MB; Abarelix Study Group. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 2002 Apr;167(4):1670-4. doi: 10.1097/00005392-200204000-00021. PMID: 11912385.

Additional Information

λmax: 226 nm